Destructive potential of the aspartyl protease cathepsin D in MHC class II-restricted antigen processing

被引:53
作者
Moss, CX
Villadangos, JA
Watts, C [1 ]
机构
[1] Univ Dundee, Wellcome Trust Bioctr, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland
[2] Walter & Eliza Hall Inst Med Res, Div Immunol, Parkville, Vic, Australia
[3] Walter & Eliza Hall Inst Med Res, Cooperat Res Ctr Vaccine Technol, Parkville, Vic, Australia
基金
英国惠康基金;
关键词
cathepsin D; cathepsin E; antigen processing; MHC class II; destructive processing;
D O I
10.1002/eji.200535320
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Whether specific proteases influence MHC class II antigen presentation is still not clearly defined. Cathepsin D, one of the most abundant lysosomal proteases, is thought to be dispensable for MHC class II antigen presentation, yet in vitro digestions of antigen substrates with endosomes/lysosomes from antigen-presenting cells sometimes reveal a dominant role for pepstatin-sensitive aspartyl proteases of which cathepsin D is the major representative. We tested whether the aspartyl protease substrate myoglobin requires cathepsin D activity for presentation to T cells. Surprisingly, in dendritic cells (DC) lacking cathepsin D, presentation of two different myoglobin T cell epitopes was enhanced rather than hindered. This paradox is resolved by the finding that pepstatin-sensitive myoglobin processing activity persists in lysosomes from cathepsin D-null DC and that this reduced activity, most likely due to cathepsin E, is closer to the optimum level required for myoglobin antigen presentation. Our results indicate redundancy among lysosomal aspartyl proteases and show that while processing activities can be productive for MHC class II T cell epitope generation at one level, they can become destructive above an optimal level.
引用
收藏
页码:3442 / 3451
页数:10
相关论文
共 48 条
[1]   Control of antigen presentation by a single protease cleavage site [J].
Antoniou, AN ;
Blackwood, SL ;
Mazzeo, D ;
Watts, C .
IMMUNITY, 2000, 12 (04) :391-398
[2]   Evolutionary conserved cathepsin E substrate specificity as defined by N-terminal and C-terminal sequencing of peptide pools [J].
Arnold, D ;
Keilholz, W ;
Schild, H ;
Dumrese, T ;
Stevanovic, S ;
Rammensee, HG .
BIOLOGICAL CHEMISTRY, 1997, 378 (08) :883-891
[3]  
Beck H, 2001, EUR J IMMUNOL, V31, P3726, DOI 10.1002/1521-4141(200112)31:12<3726::AID-IMMU3726>3.0.CO
[4]  
2-O
[5]   ANTIGEN PROCESSING FOR PRESENTATION BY CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX REQUIRES CLEAVAGE BY CATHEPSIN-E [J].
BENNETT, K ;
LEVINE, T ;
ELLIS, JS ;
PEANASKY, RJ ;
SAMLOFF, IM ;
KAY, J ;
CHAIN, BM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (06) :1519-1524
[6]   Class II MHC peptide loading by the professionals [J].
Bryant, P ;
Ploegh, H .
CURRENT OPINION IN IMMUNOLOGY, 2004, 16 (01) :96-102
[7]   The expression and function of cathepsin E in dendritic cells [J].
Chain, BM ;
Free, P ;
Medd, P ;
Swetman, C ;
Tabor, AB ;
Terrazzini, N .
JOURNAL OF IMMUNOLOGY, 2005, 174 (04) :1791-1800
[8]   Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas [J].
Chuman, Y ;
Bergman, AC ;
Ueno, T ;
Saito, S ;
Sakaguchi, K ;
Alaiya, AA ;
Franzén, B ;
Bergman, T ;
Arnott, D ;
Auer, G ;
Appella, E ;
Jörnvall, H ;
Linder, S .
FEBS LETTERS, 1999, 462 (1-2) :129-134
[9]   Inhibition of human napsin A [J].
Cronshaw, RF ;
Schauer-Vukasinovic, V ;
Powell, DJ ;
Giller, T ;
Bur, D ;
Kay, J .
PROTEIN AND PEPTIDE LETTERS, 2003, 10 (01) :35-42
[10]  
DAVIDSON HW, 1990, J IMMUNOL, V144, P4101